PEPG
PepGen Inc. NASDAQ Listed May 6, 2022$1.57
-4.55%
vs $1.65
Mkt Cap $108.9M
52w Low $1.01
8.3% of range
52w High $7.80
50d MA $2.96
200d MA $4.02
P/E (TTM)
-0.8x
EV/EBITDA
—
P/B
0.5x
Debt/Equity
0.1x
ROE
-60.8%
P/FCF
-0.9x
RSI (14)
—
ATR (14)
—
Beta
2.34
50d MA
$2.96
200d MA
$4.02
Avg Volume
1.2M
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
245 Main Street · Boston, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | AMC | -0.31 | -0.26 | +16.1% | 1.68 | -3.0% | +6.0% | -7.3% | — | — | — | — |
| Mar 4, 2026 | AMC | -0.40 | -0.27 | +32.5% | 6.76 | -18.5% | -18.5% | +3.3% | -2.1% | +10.6% | +2.1% | — |
| Nov 12, 2025 | AMC | -0.63 | -0.52 | +17.5% | 5.13 | -1.4% | -4.7% | -3.1% | +12.9% | +7.3% | -3.7% | — |
| Aug 7, 2025 | AMC | -0.85 | -0.70 | +17.6% | 1.19 | -0.8% | -10.1% | -5.6% | +12.9% | -0.9% | +14.2% | — |
| May 8, 2025 | AMC | -0.72 | -0.92 | -27.8% | 1.54 | -1.3% | -2.6% | +0.7% | +1.3% | -9.8% | +3.6% | — |
| Feb 24, 2025 | AMC | -0.81 | -0.68 | +16.0% | 2.29 | +3.1% | -25.3% | -10.5% | +58.8% | +29.6% | -10.8% | — |
| Nov 7, 2024 | AMC | -0.87 | -0.66 | +24.1% | 5.63 | -3.0% | -11.0% | -0.4% | -9.0% | +0.2% | -1.3% | — |
| Aug 8, 2024 | AMC | -0.72 | -0.87 | -20.8% | 8.98 | +1.1% | -4.3% | +0.3% | -10.1% | +7.5% | +8.9% | — |
| May 14, 2024 | AMC | -0.74 | -0.63 | +14.9% | 13.99 | +2.6% | -1.2% | -1.2% | -3.6% | +2.5% | +3.0% | — |
| Mar 6, 2024 | AMC | -1.01 | -0.82 | +18.8% | 15.41 | -1.4% | -8.0% | +0.4% | -0.8% | -1.7% | -1.0% | — |
| Nov 8, 2023 | AMC | -0.88 | -0.98 | -11.4% | 4.48 | -2.9% | -9.2% | -5.2% | +12.4% | -0.9% | -1.4% | — |
| Aug 8, 2023 | AMC | -0.81 | -0.82 | -1.2% | 5.13 | +0.0% | +2.5% | +0.8% | +5.3% | -0.7% | +6.0% | — |
| May 11, 2023 | AMC | -0.79 | -0.69 | +12.7% | 14.24 | +1.9% | +3.2% | +2.0% | -3.3% | +0.1% | +3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1 | Wedbush | Maintains | Outperform → Outperform | — | $1.77 | $1.81 | +2.3% | -1.7% | -0.6% | +5.2% | -8.2% | -0.6% |
| Mar 31 | Wedbush | Maintains | Outperform → Outperform | — | $4.23 | $2.01 | -52.5% | -58.2% | -1.7% | -0.6% | +5.2% | -8.2% |
| Feb 18 | Guggenheim | Maintains | Buy → Buy | — | $6.79 | $6.77 | -0.3% | -3.7% | +1.8% | -6.6% | +1.9% | -0.3% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.13 | $5.06 | -1.4% | -4.7% | -3.1% | +12.9% | +7.3% | -3.7% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.57 | $5.31 | +16.2% | +18.8% | -8.3% | -9.4% | +0.4% | +2.9% |
| Sep 30 | Wedbush | Maintains | Outperform → Outperform | — | $4.64 | $4.50 | -3.0% | -0.4% | +1.9% | +7.9% | +1.0% | -3.3% |
| Sep 25 | Wedbush | Maintains | Outperform → Outperform | — | $2.66 | $5.90 | +121.8% | +121.1% | -13.8% | -8.5% | -0.4% | +1.9% |
| Sep 25 | Stifel | Maintains | Buy → Buy | — | $2.66 | $5.90 | +121.8% | +121.1% | -13.8% | -8.5% | -0.4% | +1.9% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.66 | $5.90 | +121.8% | +121.1% | -13.8% | -8.5% | -0.4% | +1.9% |
| Sep 24 | Guggenheim | Maintains | Buy → Buy | — | $1.95 | $1.95 | +0.0% | +36.4% | +121.1% | -13.8% | -8.5% | -0.4% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.58 | $1.57 | -0.6% | +5.7% | -12.6% | -1.4% | +6.2% | -1.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.52 | -1.3% | -2.6% | +0.7% | +1.3% | -9.8% | +3.6% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.37 | $2.61 | +90.5% | +67.2% | -25.3% | -10.5% | +58.8% | +29.6% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.84 | $1.81 | -1.6% | -21.7% | -10.4% | -3.1% | +0.0% | +7.2% |
| Dec 16 | BofA Securities | Downgrade | Neutral → Underperform | — | $4.68 | $2.90 | -38.0% | -3.6% | -4.7% | -5.6% | +0.7% | -11.2% |
| Nov 18 | BofA Securities | Maintains | Neutral → Neutral | — | $4.12 | $4.20 | +1.9% | +0.2% | +8.2% | -1.6% | -1.8% | +2.1% |
| Nov 8 | Wedbush | Maintains | Outperform → Outperform | — | $5.63 | $5.46 | -3.0% | -11.0% | -0.4% | -9.0% | +0.2% | -1.3% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.63 | $5.46 | -3.0% | -11.0% | -0.4% | -9.0% | +0.2% | -1.3% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.43 | $11.16 | -2.4% | -11.9% | -2.6% | -5.5% | +1.3% | -5.4% |
| Jul 31 | Wedbush | Maintains | Outperform → Outperform | — | $16.98 | $10.26 | -39.6% | -32.7% | -11.9% | -2.6% | -5.5% | +1.3% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.99 | $14.36 | +2.6% | -1.2% | -1.2% | -3.6% | +2.5% | +3.0% |
| May 15 | Wedbush | Maintains | Outperform → Outperform | — | $13.99 | $14.36 | +2.6% | -1.2% | -1.2% | -3.6% | +2.5% | +3.0% |
| Mar 7 | Wedbush | Maintains | Outperform → Outperform | — | $15.41 | $15.20 | -1.4% | -8.0% | +0.4% | -0.8% | -1.7% | -1.0% |
| Jan 30 | Wedbush | Maintains | Outperform → Outperform | — | $7.25 | $7.49 | +3.3% | +50.8% | -8.2% | +23.5% | -5.9% | -8.8% |
| Sep 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.03 | $5.98 | -0.8% | +4.6% | +1.1% | -3.8% | +3.1% | -4.9% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.13 | $5.13 | +0.0% | +2.5% | +0.8% | +5.3% | -0.7% | +6.0% |
| Jun 14 | Wedbush | Maintains | Outperform → Outperform | — | $13.26 | $12.87 | -2.9% | -8.0% | +5.8% | -5.3% | -17.3% | -8.6% |
| Jun 14 | Stifel | Maintains | Buy → Buy | — | $13.26 | $12.87 | -2.9% | -8.0% | +5.8% | -5.3% | -17.3% | -8.6% |
| May 31 | Wedbush | Maintains | Outperform → Outperform | — | $15.78 | $14.33 | -9.2% | -5.1% | -1.5% | +9.4% | -2.9% | +3.8% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.24 | $14.51 | +1.9% | +3.2% | +2.0% | -3.3% | +0.1% | +3.0% |
| Mar 24 | Wedbush | Maintains | Outperform → Outperform | — | $16.88 | $20.00 | +18.5% | -9.8% | -16.2% | -9.9% | -0.5% | +3.8% |
| Nov 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $11.07 | $11.25 | +1.6% | +12.9% | +6.6% | +8.3% | -0.1% | +4.0% |
No insider trades available.
8-K · 2.02
!! High
PepGen Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
PEPG announced positive clinical data from an oligonucleotide therapy trial, potentially advancing its pipeline for severe neuromuscular and neurological diseases and validating its therapeutic approach.
Mar 30
8-K · 8.01
!! High
PepGen Inc. -- 8-K 8.01: Material Event / Announcement
PepGen's experimental myotonic dystrophy treatment PGN-EDODM1 faces a partial clinical hold from the FDA, restricting the ongoing Phase 2 trial and likely delaying development progress.
Mar 4
8-K · 7.01
! Medium
PepGen Inc. -- 8-K 7.01: Regulation FD Disclosure
PepGen Inc. disclosed information via Form 8-K that it explicitly states should not be interpreted as an admission of materiality, potentially limiting investor reliance on the disclosed details.
Mar 4
Data updated apr 26, 2026 7:15pm
· Source: massive.com